The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Brookdale Senior Living (BKD) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Brookdale Senior Living is a member of our Medical group, which includes 891 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Brookdale Senior Living is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for BKD's full-year earnings has moved 90.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, BKD has gained about 30.4% so far this year. At the same time, Medical stocks have lost an average of 5.5%. This means that Brookdale Senior Living is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Coherus Oncology (CHRS). The stock is up 32.4% year-to-date.
Over the past three months, Coherus Oncology's consensus EPS estimate for the current year has increased 9.6%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Brookdale Senior Living is a member of the Medical - Nursing Homes industry, which includes 2 individual companies and currently sits at #4 in the Zacks Industry Rank. On average, this group has gained an average of 17% so far this year, meaning that BKD is performing better in terms of year-to-date returns.
On the other hand, Coherus Oncology belongs to the Medical - Biomedical and Genetics industry. This 436-stock industry is currently ranked #89. The industry has moved +2.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Brookdale Senior Living and Coherus Oncology as they could maintain their solid performance.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Brookdale Senior Living Inc. (BKD): Free Stock Analysis Report
Coherus Oncology, Inc. (CHRS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).